YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Sanofi moves to purchase hemophilia drug maker

Posted online

French drug maker Sanofi announced Monday the planned acquisition of biopharmaceutical company Bioverativ.

Sanofi agreed to pay $11.6 billion for Bioverativ, which is known for its treatments for hemophilia and other rare blood disorders.

Sanofi is said to be using acquisitions to build its portfolio, particularly because of declining sales for its diabetes drug, Lantus, which has lost its patent protection.

Read more from The New York Times.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Annual downtown holiday events combine for Nov. 21 celebration

Organizers hope to bolster client traffic to center city businesses.

Most Read
SBJ.net Poll
How often do you use artificial intelligence for your business?

*

View results

Update cookies preferences